[Skip to Navigation]
[Skip to Navigation Landing]
January 1961

Fibrinolysin Therapy: Critical Thrombolytic Dosages and Blood Levels

Author Affiliations

From Surgical Services, West Roxbury Veterans Administration and the Peter Bent Brigham Hospitals, and from the Department of Surgery, Harvard Medical School.; Fellow in Vascular Surgery, Peter Bent Brigham and West Roxbury Veterans Administration Hospitals, and Research Assistant in Surgery, Harvard Medical School (Dr. Ouchi); Chief Research Biochemist, West Roxbury Veterans Administration Hospital (Mr. Belko); Chief, Surgical Service, West Roxbury Veterans Administration Hospital, Visiting Surgeon, Peter Bent Brigham Hospital, and Clinical Professor of Surgery, Harvard Medical School (Dr. Warren).

Arch Surg. 1961;82(1):88-96. doi:10.1001/archsurg.1961.01300070092012

Introduction  Recent advances in the production of potent fibrinolytic materials of human origin1 have resulted in their increasing administration to patients with thromboembolic disorders.The doses of these materials which have been recommended have been somewhat arbitrary, since they are based on clinical trials under circumstances where the results of the trials have been difficult to assay, as is generally true in patients with thromboembolism.2 In only a few of the trials has an effort been made to correlate clinical results with peripheral blood fibrinolytic activity.2,3 This has been largely due to a lack of uniformity of methods for determining this activity.3 It has also been the result of the contention that administered plasminogen and activator disappear rapidly from the peripheral blood and join themselves to the clot, where they continue to exert fibrinolytic effects in the absence of demonstrable activity in the peripheral blood.4